Zemdri™ (plazomicin)

About Emergent BioSolutions

Emergent BioSolutions is a publicly traded biopharmaceutical company specializing in medical countermeasures against public health threats, including chemical, biological, radiological, and nuclear (CBRN) agents, as well as emerging infectious diseases. The company operates through a fully integrated model encompassing development, manufacturing, and commercialization. Its portfolio includes FDA-approved products for anthrax, smallpox, botulism, and opioid overdose, positioning it as a critical partner to governments worldwide. Emergent's strategic focus is on preparedness and rapid response capabilities for health security emergencies.

Therapeutic Areas